Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...
Junovabio Secures Pre-Series A Funding for Tumor Molecular Diagnosis
Junovabio, a Shanghai-based molecular diagnostics specialist, has reportedly raised “tens of millions” of renminbi in...
Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round
China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...
Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...
Silk Round Fund and INA Invest in Indonesian Pharma Companies
The Chinese state-owned Silk Round Fund (SRF) and Indonesia’s sovereign fund INA have reportedly agreed...
LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study
Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...
Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China
China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...
CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs
CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...
Hotgen Receives NMPA Approval for HBV RNA Assay Kit
China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced that it has received marketing approval...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...
Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...
Yabao Receives FDA Clearance for Generic Nexavar
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...
Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...
Sansure Biotech Partners with UBC to Manufacture in Indonesia
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has entered into a local manufacturing...
HutchMed Shifts Focus to Late-Stage Pipeline for Regulatory Approvals
Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced a strategic shift to focus...
Harbour BioMed and WuXi Biologics Announce Strategic Collaboration
Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...
Hengrui’s Pyrotinib Granted Priority Review for HER2-Positive Breast Cancer
The Center for Drug Evaluation (CDE) website has announced that China-based Hengrui Pharmaceuticals’ (SHA: 600276)...
CDE Issues Guidelines for Bispecific Antibody Antitumor Drug Development
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...
AstraZeneca to Launch Soliris in Hangzhou After Regulatory Approval
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab)...
Akeso Biopharma’s AK112 Receives Two New Breakthrough Therapy Designations
The Center for Drug Evaluation (CDE) website indicates that China-based Akeso Biopharma (HKG: 9926) has...